Expanding markets in Asia continue to spur investment in facilities and R&d in the region. The latest example comes from Merck's announcment that it will spend $250 M in Singapore to expand its biotech operations, add new technology to support product launches, and collaborate with more local universities to develop its workforce.
The Singapore Economic Development Board (SEDB) is backing Merck's expansion as part of its goal to draw more biomanufacturing to the country. Previously, the SEDB has been successful in getting Lonza to invest in facilities in Singapore (one of which was later purchased by Roche).
"We are encouraged that this will pave the way for Singapore to continue to enhance our capabilities as an integrated global pharmaceutical site in Asia", said Beth Swan Gin, managing director of SEDB.
Posted by Bruce Lehr Oct 24th 2011.